Abstract
Henoch–Schönlein purpura (HSP) is one of the most common causes of systemic vasculitis in children. The incidence of HSP nephritis (HSPN) among HSP patients has been reported to be 15–62%. Even so, what constitutes severe HSPN is controversial. In the study reported here, we retrospectively reviewed the clinical features and prognosis of 101 children with HSPN, ISKDC grade IIIa/IIIb, from January 1992 to November 2008. Patients with isolated hematuria and/or proteinuria <50 mg/kg/day received triptolide alone, and those with nephrotic range proteinuria received a combination therapy of prednisone and triptolide. Nephrotic syndrome was the most common clinical manifestation (45.5%). There were no significant differences in the clinical features (χ2 = 2.756, P = 0.252), the side effects related to treatment (χ2 = 2.259, P = 0.894), prognosis between IIIa and IIIb (χ2 = 3.013, P = 0.222), or prognosis in grade IIIa patients receiving triptolide alone or triptolide and prednisone (χ2 = 1.207, P = 0.272) and grade IIIb patients (χ2 = 1.158, P = 0.282). No significant difference in clinical manifestations and long-term prognosis of our HSPN patients with grade IIIa or grade IIIb were found, implying that our patients with International Study and Kidney Disease in Children (ISKDC) grade IIIb were not the most severe cases of HSPN. Our results may also suggest that treatment with steroid may not alter the clinical outcome of such grade IIIa or IIIb patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shenoy M, Bradbury MG, Lewis MA, Webb NJ (2007) Outcome of Henoch–Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 22:1717–1722
Bogdanovic R (2009) Henoch–Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr 98:1882–1889
Assadi F (2009) Childhood Henoch–Schönlein nephritis: a multivariate analysis of clinical features and renal morphology at disease onset. Iran J Kidney Dis 3:17–21
Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H (2003) Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch–Schönlein nephritis. Pediatrics 111:785–789
Tarshish P, Bernstein J, Edelmann CM Jr (2004) Henoch–Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56
Kawasaki Y, Suzuki J, Suzuki H (2004) Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch–Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant 19:858–864
Ronkainen J, Autio-Harmainen H, Nuutinen M (2003) Cyclosporin A for the treatment of severe Henoch–Schönlein glomerulonephritis. Pediatr Nephrol 18:1138–1142
Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein–Henoch purpura nephritis. Pediatr Nephrol 12:238–243
Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N (1998) Multiple combined therapy for severe Henoch–Schönlein nephritis in children. Pediatr Nephrol 12:244–248
Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C (1977) Prognosis of Henoch–Schönlein nephritis in children. Br Med J 2:11–14
Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch–Schönlein purpura. Arthritis Rheum 33:1114–1121
Meadow SR, Glasgow EF, White RH, Moncrieff MW, Cameron JS, Ogg CS (1972) Schönlein–Henoch nephritis. Q J Med 41:241–258
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576
Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, Wang S, Wang J, Zhu X, Liu Z (2010) Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant 25:3539–3547
Xu G, Tu W, Jiang D, Xu C (2009) Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract 111:c223–228
Tao X, Lipsky PE (2000) The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 26:29–50, viii
Jiang X (1994) Clinical observations on the use of the Chinese herb Tripterygium wilfordii Hook for the treatment of nephrotic syndrome. Pediatr Nephrol 8:343–344
Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, Xu CG, Sun LL, Mei CL (2010) Meta-analysis of Tripterygium wilfordii hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med 49:2049–2055
Acknowledgments
The project was supported by National Natural Science Foundation of China (Grant No. 30971365 & 81070561), Zhejiang Provincial Healthy Science Foundation of China (Grant No. 2008ZX006 & WKJ2010-2-014), Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents, and The Fundamental Research Funds for Zhejiang University(5A7000*172210101). We thank all patients who participated in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xia, Y., Mao, J., Chen, Y. et al. Clinical outcomes in children with Henoch–Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol 26, 1083–1088 (2011). https://doi.org/10.1007/s00467-011-1834-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-011-1834-9